Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective study analysing risk of birth defects and perinatal outcomes in HIV-infected women exposed to integrase strand inhibitors during pregnancy

Next Previous
X
Search
Trial Profile

A prospective study analysing risk of birth defects and perinatal outcomes in HIV-infected women exposed to integrase strand inhibitors during pregnancy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Oct 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abacavir (Primary) ; Cobicistat/elvitegravir (Primary) ; Darunavir (Primary) ; Darunavir/ritonavir (Primary) ; Dolutegravir (Primary) ; Elvitegravir (Primary) ; Emtricitabine (Primary) ; Raltegravir (Primary) ; Ritonavir (Primary) ; Tenofovir (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 21 Oct 2020 New trial record
    • 08 Oct 2020 Results published in the AIDS

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top